Document Detail

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
MedLine Citation:
PMID:  17444848     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND AIM: Inhibition of tumor necrosis factor (TNF)-alpha is a logical approach to manage patients with non-alcoholic steatohepatitis (NASH). Pentoxifylline reduces TNF-alpha and alanine aminotransferase (ALT) levels in patients with NASH. The aim of the present paper was to study if pentoxifylline can improve histological injury in patients with NASH. METHODS: Nine patients (mean age 31.6 +/- 7.2 years) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxyfylline at a dosage of 400 mg t.i.d. for 12 months. Besides biochemical assessment, a repeat liver biopsy was performed and the degree of inflammation and fibrosis was compared. RESULTS: After 12 months of therapy a significant reduction in ALT (111 +/- 53 IU/L vs 45 +/- 19 IU/L, P = 0.003) and aspartate aminotransferase (AST) (61 +/- 27 IU/L vs 33 +/- 12 IU/L, P = 0.005) levels was observed. Steatosis and lobular inflammation each reduced in 55% and six (67%) patients down-staged on Brunt's staging (P = 0.009). Four out of six patients with baseline fibrosis had reduction in their fibrosis stage. CONCLUSIONS: Long-term pentoxyfylline therapy effectively achieves sustained biochemical improvement. This correlates well with histological resolution of the disease.
Sanjaya K Satapathy; Puja Sakhuja; Veena Malhotra; Barjesh C Sharma; Shiv K Sarin
Related Documents :
12787798 - Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis c: a pilo...
16400348 - Osteoporosis in liver cirrhosis.
12097458 - Detection of neuroendocrine tumors: 99mtc-p829 scintigraphy compared with 111in-pentetr...
8013098 - Alkaline phosphatase isoforms in serum after liver allograft surgery.
14765938 - Should carotid endarterectomy be performed for symptomatic carotid stenosis in pakistan?
12599088 - Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infec...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  22     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-20     Completed Date:  2007-07-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  634-8     Citation Subset:  IM    
Department of Gastroenterology, GB Plant Hospital, New Delhi, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Fatty Liver / complications,  drug therapy*,  enzymology,  pathology
Hepatitis / complications,  drug therapy*,  enzymology,  pathology
Liver / drug effects*,  enzymology,  pathology
Liver Cirrhosis / drug therapy*,  enzymology,  etiology,  pathology
Pentoxifylline / administration & dosage,  therapeutic use*
Protective Agents / administration & dosage,  therapeutic use*
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Protective Agents; 6493-05-6/Pentoxifylline; EC Aminotransferases; EC Transaminase
Comment In:
J Gastroenterol Hepatol. 2007 May;22(5):613-4   [PMID:  17444846 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bruising: when it is spontaneous and not idiopathic thrombocytopenia purpura.
Next Document:  Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five...